Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05815485
Status:
RECRUITING
Last Update Posted:
2023-10-31
First Post:
2023-04-13
Brief Title:
A Randomized Double-Blind Placebo-Controlled Phase 23 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 COVID-19 or Pneumonia
Sponsor:
Salim S Hayek
Organization:
University of Michigan
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase 23 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 COVID-19 or Pneumonia
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers dont know In this study they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None